TY - JOUR AU - Kataoka, Yuki AU - Hirano, Katsuya PY - 2018 TI - Which criteria should we use to evaluate the efficacy of immunecheckpoint inhibitors? JF - Annals of Translational Medicine; Vol 6, No 11 (June 16, 2018): Annals of Translational Medicine Y2 - 2018 KW - N2 - Immune-checkpoint inhibitors (ICI) have innovated the treatment of many different types of advanced cancer. Two important distinctions between ICI and other modalities are durable response (DR) and pseudoprogression (1,2). UR - https://atm.amegroups.org/article/view/19463